Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent small-molecule inhibitor targeting Rho-associated protein kinases ROCK1 and ROCK2, with an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, demonstrating over 200-fold selectivity versus non-ROCK kinases (product data; A3008). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression from G1 to S phase in vitro (product data; source). Y-27632 is widely used to study cytoskeletal organization, enhance stem cell viability, and suppress tumor invasion and metastasis in preclinical models (Hinderling et al., 2025). It is highly soluble in DMSO, ethanol, and water, with best storage as a desiccated solid at 4°C or below (product data). Its selectivity and performance are benchmarked in multiple comparative studies (site article).

Biological Rationale

Cellular behavior is tightly regulated by intracellular signaling pathways. The Rho/ROCK pathway modulates actin cytoskeleton dynamics, cell shape, migration, and survival. Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases acting downstream of the small GTPase RhoA. Dysregulation of the Rho/ROCK axis is linked to altered cell proliferation, abnormal cytokinesis, and increased tumor cell invasion (Hinderling et al., 2025). Targeting ROCK kinases enables researchers to dissect cytoskeletal mechanisms, study tissue morphogenesis, and model disease progression. Y-27632 dihydrochloride, as a selective inhibitor, serves as a key tool for manipulating these processes in vitro and in vivo.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride inhibits the catalytic domains of ROCK1 and ROCK2, blocking their kinase activity. It binds competitively at the ATP-binding site, preventing phosphorylation of downstream targets such as myosin light chain (MLC). This inhibition disrupts actomyosin contractility, leading to loss of stress fiber formation and altered cell morphology. The compound demonstrates an IC50 of ~140 nM for ROCK1 and a Ki of 300 nM for ROCK2, with more than 200-fold selectivity against other kinases including PKC, cAMP-dependent protein kinase, MLCK, and PAK (A3008). By modulating ROCK signaling, Y-27632 interferes with cell cycle progression (G1/S transition), impacts cytokinesis, and reduces cell migration and invasion (Hinderling et al., 2025).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC50 of approximately 140 nM in biochemical assays (product data; A3008).
• Ki for ROCK2 inhibition is 300 nM, confirming selectivity among Rho-associated kinases (A3008).
• Shows >200-fold selectivity against kinases PKC, cAMP-dependent protein kinase, MLCK, and PAK (selectivity assays; A3008).
• Disrupts Rho-mediated formation of stress fibers and focal adhesions in fibroblasts in vitro (Hinderling et al., 2025).
• Reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner in culture (product technical note; A3008).
• Inhibits tumor invasion and metastasis in mouse xenograft models, reducing pathological structures (Hinderling et al., 2025).
• Enhances stem cell viability and survival during in vitro expansion (site article).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is deployed in research to:

• Study Rho/ROCK signaling pathway in cytoskeletal dynamics and cell morphology.
• Enhance stem cell survival, especially during cell passaging and single-cell cloning.
• Suppress tumor cell invasion and metastasis in preclinical cancer models.
• Facilitate cell proliferation assays and studies of cell migration.
• Modulate cytokinesis and study cell cycle checkpoints.

This article extends previous reviews such as Y-27632 Dihydrochloride: Selective ROCK Inhibition for Cytoskeletal Studies by providing quantitative selectivity data and updated in vivo benchmarks. For advanced mechanistic insights into neurodegeneration, see Y-27632 Dihydrochloride: Precision ROCK Inhibition in Neurobiology; this present article clarifies the compound's broader applicability across cell lineages and cancer models. For a comprehensive reference on translational and regenerative applications, see this strategic review contrasting Y-27632's performance with next-generation ROCK inhibitors.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all serine/threonine kinases; its activity is highly selective for ROCK1/2 and not suitable for studies targeting PKC, MLCK, or PAK.
• The compound does not induce apoptosis directly; its effects on cell viability in stem cells are via cytoskeletal stabilization, not cytotoxicity.
• Y-27632's in vivo bioavailability and pharmacokinetics are not fully characterized for therapeutic use; its primary utility is in cell-based research and animal models.
• Long-term storage of Y-27632 solutions is not recommended due to potential hydrolysis and loss of potency.
• It is not effective in models where ROCK-independent pathways predominate in cytoskeletal regulation.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. It is highly soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Warming at 37°C or sonication can enhance solubility. Stock solutions are stable below -20°C for several months, but long-term storage of working solutions is discouraged. For cell culture, typical working concentrations range from 1 μM to 30 μM, depending on cell type and assay. Use fresh dilutions for each experiment to ensure maximal activity. For detailed protocol and product ordering, refer to the Y-27632 dihydrochloride (A3008) product page.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard reagent for dissecting Rho/ROCK signaling in both basic and translational research. Its selectivity profile and robust performance in cytoskeletal, stem cell, and cancer assays are well established. Ongoing advances in microfabrication and high-throughput screening are expanding its utility for standardized cell and tissue models (Hinderling et al., 2025). Researchers should consider Y-27632's specificity and storage guidelines when designing experiments. Future studies may further clarify its in vivo pharmacology and potential for clinical translation.